Icatibant Acetate CAS:138614-30-9

Icatibant acetate is specifically indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults. It is not intended for routine prophylaxis or for the treatment of other forms of angioedema. When an individual experiences the onset of symptoms associated with an acute HAE attack, such as localized swelling of the skin or mucous membranes, they can self-administer icatibant acetate via subcutaneous injection. The typical recommended dose is 30 mg, injected into the fatty tissue of the abdomen. If necessary, a second dose may be administered after 6 hours, provided that it is injected at a different site than the initial injection. It's important for individuals prescribed icatibant acetate to receive appropriate training on how to safely and effectively administer the medication themselves, as prompt administration during an HAE attack is crucial for symptom relief. Before using icatibant acetate, patients should inform their healthcare provider of any known allergies or hypersensitivity reactions to this medication or its components. Additionally, individuals with a history of heart disease or risk factors for cardiovascular events should use icatibant acetate with caution and under close medical supervision. While the most common side effects of icatibant acetate include mild local reactions at the injection site, such as redness, swelling, and itching, individuals should seek medical attention if they experience more severe reactions or if their HAE symptoms do not improve after the initial dose. Overall, icatibant acetate provides a targeted approach to managing acute HAE attacks, offering individuals a means to alleviate the often debilitating symptoms associated with this condition in a timely and efficient manner. Regular communication with healthcare providers and adherence to proper injection techniques are essential for maximizing the benefits of icatibant acetate in the management of HAE.